Clinical trial / 2018
Amla tablets significantly reduced the frequency and severity of heartburn and regurgitation compared to placebo in patients with non-erosive reflux disease.
A double-blind, randomized, placebo-controlled trial evaluated the efficacy of Amla (Phyllanthus emblica L.) tablets in 68 patients with non-erosive reflux disease. Participants took two 500 mg Amla tablets or placebo twice daily after meals for 4 weeks. Heartburn and regurgitation frequencies significantly dropped in both groups (P < 0.001), but repeated measures logistic regression demonstrated a significantly greater reduction in the frequency and severity of both heartburn and regurgitation in the Amla group compared to placebo (P < 0.001).
- Study type
- Double-blind, randomized, placebo-controlled trial
- Who was studied
- 68 patients with classic GERD symptoms for at least three months
- What was measured
- Frequency and severity of heartburn and regurgitation
THE PAPER
Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
Karkon Varnosfaderani S, Hashem-Dabaghian F, Amin G, Bozorgi M, Heydarirad G, Nazem E, Nasiri Toosi M, Mosavat SH. J Integr Med, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.